Protara Therapeutics, Inc.
Data quality: 83%
TARA
Nasdaq
Manufacturing
Chemicals
$5.27
▲
$0.05
(0.96%)
Mkt Cap: 285.02 M
Price
$5.27
Mkt Cap
285.02 M
Day Range
$5.16 — $5.29
52-Week Range
$2.77 — $7.82
Volume
260,566
Open $5.19
50D / 200D Avg
$6.02
12.43% below
50D / 200D Avg
$4.82
9.45% above
Quick Summary
Key Takeaways
Negative free cash flow of -56.46 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-41.52%
Above sector avg (-53.41%)
ROIC-36.18%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio13.69
Interest CoverageN/A
Valuation
PE (TTM)
-4.96
Below sector avg (-1.48)
P/B Ratio2.15
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -5.0 | -1.5 |
| P/B | 2.2 | 1.6 |
| ROE % | -41.5 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
ETFs Holding This Stock
0.01% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -57.44 M |
| ROE | -41.52% | ROA | -38.09% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -56.46 M |
| ROIC | -36.18% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 13.69 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 125.74 M | Tangible Book Value | 132.29 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4.96 | Forward P/E | N/A |
| P/B Ratio | 2.15 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -19.81% | ||
| Market Cap | 285.02 M | Enterprise Value | 272.47 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.34 | Revenue / Share | N/A |
| FCF / Share | -1.04 | OCF / Share | -1.04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 98.29% |
| SBC-Adj. FCF | -60.17 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -57.44 M | -44.60 M | -40.42 M | -65.95 M | -47.25 M |
| EPS (Diluted) | -1.34 | -2.17 | -3.57 | -5.86 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -64.55 M | -49.15 M | -43.61 M | -67.06 M | -47.49 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 42.63 M | 31.70 M | 24.99 M | 16.81 M | 21.09 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | 0.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 209.47 M | 181.45 M | 78.95 M | 113.29 M | 172.60 M |
| Total Liabilities | 13.06 M | 14.32 M | 10.63 M | 11.21 M | 10.68 M |
| Shareholders' Equity | 196.41 M | 167.13 M | 68.32 M | 102.08 M | 161.91 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 49.66 M | 162.80 M | 39.59 M | 24.13 M | 35.72 M |
| Current Assets | 159.50 M | 172.16 M | 68.71 M | 86.15 M | 93.11 M |
| Current Liabilities | 10.94 M | 10.96 M | 6.15 M | 5.74 M | 4.30 M |
{"event":"ticker_viewed","properties":{"ticker":"TARA","listing_kind":"stock","pathname":"/stocks/tara","exchange":"Nasdaq","country":"US"}}